Studies towards the identification of potent, selective and bioavailable thrombin inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 5, 1999, Pages 737-742

  Ambler, J ^a   Baker, E ^a   Bentley, D ^a   Brown, L ^a   Butler, K ^a   Butler, P ^a   Farr, D ^a   Dunnet, K ^a   Le Grand, D ^a   Hayler, J ^a   Janus, D ^a   Jones, D ^a   Menear, K ^a   Mercer, M ^a   Smith, G ^a   Talbot, M ^a   Tweed, M ^a  

^a Novartis Institutes for BioMedical Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; MACROGOL 400; PHENYLALANINE; PIPERIDINE DERIVATIVE; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; INTRADUODENAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHARMACOPHORE; PHYSICAL CHEMISTRY; RAT; STRUCTURE ACTIVITY RELATION; VEIN THROMBOSIS;

ANIMALIA;

EID: 0033535388     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00061-X     Document Type: Article

References (15)

1. Akikazu Takada Yumiko Takada Tetsumei Urano The physiological aspects of fibrinolysis Thromb. Res. 76 1 1994 1 31
2. Brigitte Kaiser Thrombin and factor Xa inhibitors Drugs of the Future 23 4 1998 423 436
3. G.G. Turpie Alexander I. Weitz Jeffrey Jack Hirsh Advances in antithromobotic therapy: novel agents Thromb. Haemostasis 74 1 1995 565 571
4. J.W. Fenton II F.A. Ofosu D.G. Moon J.M. Maraganore Thrombin structure and function: why thrombin is the primary target for antithrombotics Blood Coagulation Fibrinolysis 2 1 1991 69 75
5. H.O. Ammar M. Ghorab S.A. El-Nahhas T.S. Makram Improvement of the biological performance of oral anticoagulant drugs Part 1. Warfarin. Pharmazie 52 8 1997 627 631
6. J. Hirsh Heparins. Fibrinolysis 9 Suppl. 1 1995 66 68
7. nd ed. 1992 Publisher Dekker, New York, N.Y 63 84
8. S.D. Kimball Challenges in the development of orally bioavailable thrombin active site inhibitors Blood Coagulation Fibrinolysis 6 6 1995 511 519
9. William C. Ripka George P. Vlasuk Antithrombotics/serine proteases Annu. Rep. Med. Chem. 32 1997 71 89
10. John. Ambler Emma Baker Lyndon. Brown Paul. Butler Dave. Farr Karen. Dunnet Darren Le Grand Diana. Janus Darryl. Jones Keith. Menear Mark. Mercer Garrick. Smith Mark. Talbot Morris Tweed The Discovery of Orally Available Thrombin Inhibitors: Studies Towards the Optimisation of CGH1668 Bioorg. Med. Chem. Lett. 8 1998 3583 3588
11. nd ed. 1993 Verlag Helvetica Chim. Acta Basel, Switz 15 25
12. Compudrug, Budapest, Hungary.
13. Dennis A. Smith Barry C. Jones Donald K. Walker Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics Med. Res. Rev. 16 3 1996 243 266
14. Sidney D. Lewis Assunta S. Ng Elizabeth A. Lyle Michael J. Mellott Sandra D. Appleby Stephen F. Brady Kenneth J. Stauffer John T. Sisko Shi-Shan Mao Inhibition of thrombin by peptides containing Lysyl-a-keto carbonyl derivatives Thromb. Haemostasis 74 4 1995 1107 1112
15. Thomas J. Tucker William C. Lumma S.Dale Lewis Stephen J. Gardell Bobby J. Lucas Elizabeth P. Baskin Richard Woltmann Joseph J. Lynch Elizabeth A. Lyle Sandra D. Appleby I-Wu Chen Kimberley B. Dancheck Joseph P. Vacca Potent Noncovalent Thrombin Inhibitors That Utilize the Unique Amino Acid D-Dicyclohexylalanine in the P3 Position. Implications on Oral Bioavailability and Antithrombotic Efficacy J. Med. Chem. 40 11 1997 1565 1569